Background: Orally inhaled corticosteroids represent the usually recommended initial controller therapy for most patients with persistent asthma. Some patients might benefit from earlier use of a combination of an inhaled corticosteroid and an orally inhaled longacting b agonist, however. We wished to identify clinical characteristics of patients which would enable one to identify a sub-group of patients who would benefit most from initiating sustained controller therapy with combination therapy. Methods: We carried out a secondary analysis of five randomized clinical trials including 1606 subjects in order to examine whether differences in baseline characteristics of patients might predict a greater preferential response to combination therapy with salmeterol and fluticasone. Results: Subjects whose asthma had been present for 10 or more years were 2.2 times more likely to achieve well-controlled asthma by 12 weeks on combination therapy, while subjects with a shorter duration of asthma were only 1.4 times as likely to achieve asthma control with combination therapy as opposed to inhaled corticosteroids alone. None of the other factors examined including symptom frequency or severity, rescue b-agonist use,
Introduction
Orally inhaled corticosteroids (ICS) are the preferred maintenance therapy in asthma. 1 ICS address the underlying inflammatory process and result in a rapid reduction in symptoms and improvement in lung function, although their full benefit takes several months to achieve. 2 When patients' asthma is not well controlled on low to moderate doses of inhaled corticosteroids, several trials have now conclusively demonstrated that adding an orally inhaled long-acting b 2 agonist bronchodilator (LABA) provides superior asthma control to that obtained by increasing the dose of inhaled corticosteroid, even if the dose increase is four fold. [3] [4] [5] [6] It remains unclear when it might be appropriate to start a patient, not currently on regular maintenance therapy, on combined LABA/ICS therapy rather than an ICS alone. Studies that have compared combined LABA/ICS therapy to ICS alone have provided conflicting results which might be the result of phenotypic differences in the asthma of the subjects included. For example, Pearlman in a 4-week study comparing monotherapy with fluticasone to combination therapy with salmeterol and fluticasone among patients on short-acting b agonists alone, found better lung function and symptom improvement with the combination. 7 The subjects included had, on average, asthma that was poorly controlled as attested to by the need for more than two inhalations of as needed b agonist per day and an average forced expiratory volume in the first second (FEV 1 ) of less than 70% predicted. In the recent GOAL study, 3 subjects who had not received maintenance ICS or LABA in the prior 6 months, more frequently achieved well-controlled asthma after an initial 12 weeks of salmeterol 50 mg and fluticasone 100 mg as compared to fluticasone 100 mg alone, both inhaled twice a day. Here again, subjects needed, on average, 1.8 inhalations of rescue b agonist per day at baseline and the average pre-bronchodilator FEV 1 was less than 80%.
O'Byrne and colleagues compared combined LABA/ICS controller therapy to ICS monotherapy in subjects previously on rescue short-acting b agonists alone. 8 Subjects receiving the combination of formoterol 4.5 mg and budesonide 100 mg twice a day were no better in terms of symptom free days or number of exacerbations as compared to subjects who were randomized to receive budesonide 100 mg twice a day as the only controller therapy over a period of 1 year. The average FEV 1 was 90% and subjects required, on average, less than one inhalation per day of a rescue b agonist in the last 2 weeks of the baseline period.
These contrasting studies suggest that the degree of airways obstruction and the need for rescue medication might predict which patients, not currently on maintenance therapy, but whose asthma is poorly controlled, might respond better to combined LABA/ICS therapy and in whom ICS as sole controller therapy might prove to be insufficient. We carried out a secondary analysis of several clinical trials to see whether we could identify factors which would allow us to better target combined LABA/ICS therapy to those patients whom would benefit most.
Methods
We identified 2041 patients who were previously receiving short-acting b agonists alone from the intent-to-treat populations of five randomized controlled trials carried out by Glaxo-Smith-Kline comparing the combination of salmeterol 50 mg and fluticasone 100 mg bid to fluticasone 100 mg bid as the only controller therapy. The majority (53%) were patients from stratum 1 of the GOAL study. 3 Inclusion criteria for the studies were similar. Subjects had to be at least 12 years of age, have asthma diagnosed more than 6 months ago and a maximum cumulative exposure to cigarette smoking of 10 pack years. We excluded 327 subjects because their FEV 1 was missing, or less than 60%. The latter were excluded because we were primarily interested in the role of combined maintenance therapy in subjects with at most moderate airways obstruction. We excluded a further 108 subjects for whom missing symptom diary data made evaluation of asthma control, the outcome under study, impossible leaving 1606 subjects for analysis. The outcome of interest was achieving well-controlled asthma as defined in the GOAL study in the last 2 weeks of a 12-week follow-up. Well-controlled asthma was defined each week as two or more of: (i) daytime symptoms p2 days with a symptom score of 41(1 was defined as ''symptoms for one short period during the day''); (ii) use of rescue b agonist on p2 days and p4 occasions; (iii) morning PEF X80% predicted every day. Subjects had to remain in each study for a minimum of 6 weeks. Information on a full 12 weeks was available for 96% of included subjects. For the remaining 4%, the last 2 available weeks of observation were used to determine whether well-controlled asthma had been achieved.
Baseline predictors were collected prior to randomization in each of the trials. For symptoms and rescue bronchodilator use, information from the last 7 consecutive days of run in prior to randomization was used. Baseline predictors considered a priori were age, gender, smoking history (nonsmoker, current smoker, ex-smoker), race, body mass index (BMI), duration of asthma, atopy, frequency of use of a short-acting b agonist (SABA), daily symptoms and night time awakenings in the prior week. Baseline information on ARTICLE IN PRESS the duration of asthma was collected in the following categories: 6 months to less than 1 year, 1 year to less than 5 years, 5 years to less than 10 years, 10 years to less than 15 years and 15 years or more. Information on atopy was obtained differently in the various studies. Atopy was considered to be present if there was a positive answer to a history of atopy, seasonal rhinitis, eczema or when there was evidence in the medical chart of a raised serum IgE, blood eosinophilia or positive allergy skin tests.
We used logistic regression to first explore each individual variable-by-treatment interaction to better understand the predictive ability of each potential clinical factor. Both the continuous and categorized forms of the baseline variables of interest were explored in separate models to ensure that the most informative form for each variable was included in the full multivariate model. Based on the distribution of variables, clinical plausibility, and detection of significant interactions with the treatment effect (combined salmeterol and fluticasone versus fluticasone), variables were dichotomized as shown in Table 1 .
Backwards elimination with multivariate logistic regression was used as the primary method for model selection.
Odds ratios for each level of the interaction were generated with contrasts when significant (pp0.05). As a result of high correlation between baseline predictors, multiple models were identified. These models were compared and the best model was chosen on the basis of statistical fit and clinical relevance. Once a model was selected, treatment interactions with morning peak flow (% predicted), FEV 1 (% predicted) and % reversibility of FEV 1 post bronchodilator were added to the model. These assessments of baseline pulmonary function were not included in the original model selection exercise due to a significant amount of missing data. SAS version 8.2 was used for all statistical analyses.
Ethics approval was obtained prior to participation in each trial at each participating institution.
Results
A total of 1606 patients, 790 of whom received salmeterol and fluticasone and 816 fluticasone as sole controller, were included in the present analysis. Baseline characteristics for all 1606 subjects are shown in Table 1 . The mean percentage predicted FEV 1 was 83.9% (SD ¼ 14.06) and ranged from 60.0% to 147.6%. Overall as shown in Table 2 , subjects were 80% more likely to achieve control with salmeterol and fluticasone as compared to fluticasone alone (odds ratio 1.8, 95% CI 1.46-2.18). Table 3 provides the distribution of the baseline characteristics examined according to whether subjects achieved or did not achieve well-controlled asthma at 12 weeks when randomized to receive salmeterol and fluticasone or fluticasone alone. Among the 890 subjects whose asthma had been diagnosed 10 or more years ago, 268 of the 439 (61%) subjects randomized to combination therapy achieved control as compared to 186 of 451 (41%) of subjects randomized to receive fluticasone alone. This interaction between treatment duration and treatment group was statistically significant (p ¼ 0.016). The results in Table 3 indicate that asthma duration of 10 years or longer was present in 55% of subjects controlled on combination therapy, 57% uncontrolled on combined therapy, 48% controlled on fluticasone alone and 62% uncontrolled on fluticasone alone. None of the interactions by baseline pulmonary function were statistically significant. Of note, information on FEV 1 bronchodilator reversibility was missing for 226 (14%) subjects. For subjects reporting duration of asthma of 10 years or more, there was a 2.2-fold advantage (95% CI 1.71-2.92) for combination therapy in achieving asthma control by 12 weeks of therapy. The difference between the two treatment options was less for those subjects with a shorter duration of asthma (odds ratio 1.4, 95% CI 1.01-1.84) ( Table 4 ).
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Discussion
We combined the results of available randomized clinical trials comparing combination therapy with salmeterol and fluticasone to fluticasone as sole controller therapy, in order to identify factors which might help predict which patients, not recently on regular controller therapy for asthma, would benefit most from combined LABA/ICS treatment as compared to ICS therapy alone. Overall, the patients were 1.8 times more likely to achieve well-controlled asthma within 12 weeks with combination therapy than with fluticasone alone. The benefit was more pronounced among subjects reporting a duration of asthma of 10 years or more (2.2 times more likely to achieve asthma control) as compared to those with a shorter reported duration of disease (1.4 times more likely to achieve control with combination therapy). None of the other factors examined including symptom frequency or severity, rescue b-agonist use, severity of lung function impairment or degree of reversibility, was able to distinguish subjects who would benefit more than average from combination LABA/ICS treatment as compared to ICS treatment alone. To ensure the validity of our findings, all of the potential predictors of response were defined a priori and were tested as formal statistical interactions. 9 By pooling the results of a number of studies evaluating the role of combination therapy as an initial treatment approach, this analysis has identified both a biologically plausible and easy to apply clinical predictor of benefit from initial combination controller therapy-duration of asthma. The effect size is substantial and likely to be appreciated by patients. Given the number of participants, we consider it unlikely that other predictors have been missed.
An argument can still be made that a 3-month assessment is inadequate to fully evaluate the benefits of inhaled corticosteroids alone, particularly without dose escalation. Conversely it remains possible that several of the factors examined might better predict a preferential response to Table 3 Baseline predictors of treatment advantage. Salmeterol and fluticasone, N ¼ 790 Fluticasone alone, N ¼ 816 Ã Odds ratios and 95% confidence intervals were generated from the final selected logistic regression model. combination therapy over a longer period of time. Overall, however, it is not unreasonable for physicians and their patients to expect a substantial improvement in their condition within 3 months of initiating regular controller therapy. Greater efficacy of combination LABA/ICS therapy in patients with more prolonged disease is consistent with studies suggesting that the benefits with ICS as sole controller therapy are most pronounced in the early natural history of asthma. 10, 11 Greater benefit of combination therapy is also consistent with the notion that the primary effect of the LABA component is on the smooth muscle cell, which increases in amount with more prolonged duration of asthma. 12 The increased smooth muscle mass may be indicative of the greater importance of smooth muscle contraction in the pathogenesis of symptoms of poor asthma control in individuals with a longer duration of disease, and hence the benefit of combination therapy with a LABA.
ARTICLE IN PRESS
Alternatively, there is some evidence that the increased matrix in the airway wall in asthma, which also increases with increased asthma duration, 13 contributes to the persistence of airway inflammation and airways hyperresponsiveness by facilitating retention of cytokines and chemokines and thus inflammatory cell influx. 14 This in turn predicts the need for a greater corticosteroid action to reduce proinflammatory cytokine production in long standing disease, and LABAs promote corticosteroid action. 15 The presence of airflow limitation, especially if only partially reversible, is thought to indicate remodeling. 13, 16 Somewhat surprisingly, in our data neither the degree of airflow limitation nor the degree of reversibility was associated with a differential response to combination LABA/ICS therapy. Although a large bronchodilator response may indicate patients at a higher risk of exacerbations 17 and hence expected to be predictive of a better response to dual controller therapy, this benefit was not observed in our study; perhaps because these data were not collected in all enrolled subjects. As we limited our analysis to subjects with an FEV 1 of at least 60% predicted we may have missed a preferential response to combination LABA/ICS therapy among subjects with more severe airways obstruction.
In conclusion, the results of this analysis suggest that duration of disease is a practical tool physicians can use to predict that asthmatic patients, not currently on sustained controller therapy, will derive greater benefit from a combination of inhaled steroids and long-acting b agonists than subjects with a shorter duration of asthma. It would be worthwhile to re-examine this question in completed trials of other combinations of an inhaled corticosteroid and a long-acting b-agonist.
